Zacks Investment Research | Nov 20, 2019 08:42PM ET
QIAGEN N.V. (NYSE:QGEN) entered an agreement with Laboratory Corporation of America Holdings (NYSE:LH) or LabCorp to extend their existing QIAGEN Clinical Insights (QCI) license.
Per the terms of the agreement, the QCI license will be extended for LabCorp with QIAGEN’s Human Gene Mutation Database (HGMD) of human genetic variants (the world’s largest database of inherited disease mutations). With the recent announcement, the entities deepened the seven-year agreement to develop, introduce and support new diagnostic tests.
The extended partnership will aid QIAGEN to strengthen foothold in the global next generation sequencing (NGS) market.
Few Words on NGS
NGS has become instrumental in identifying genetic variants which play a role in inherited diseases. It provides a flexible technology platform which makes it possible to use highly targeted (rather than large-scale) test panels for clinical diagnostics, and in studies of new therapies and diagnostics.
A Peek Into HGMD
More than 20 million people in the United States are currently affected by hereditary diseases. Major technological advances have already been made to enable the cost-effective generation of large datasets, encompassing all coding regions (including entire human genomes).
However, linking a patient’s genetic variants to the increasing body of knowledge of human disease genetics is becoming challenging. This limits genetic testing's ability to provide actionable information to guide diagnosis and take better treatment decisions. This makes it difficult for patients and their families to deal with the situation, highlighting the importance of the availability of genetic variation information.
HGMD is a component of QCI, which is a key source of information on heritable mutations. With the increasing cases of mutations, HGMD will provide the required information to convert variant data to actionable insights for researchers, physicians and patients.
Rationale Behind the Extended Partnership
Per the agreement, HGMD will provide access to validated evidence to support more precise and comprehensive variant interpretation of hereditary diseases. This, in turn, will help laboratories as well as patients receive answers to queries related to hereditary diseases and appropriate treatment options.
The extension of the existing partnership with LabCorp will authenticate QIAGEN’s bioinformatics solutions in the interpretation of germline diseases, thus enabling patients and their families to make more informed decisions for any germline or somatic indication for all clinical testing labs.
Recent Developments
QIAGEN announced the expansion of its QIAseq NGS portfolio in November for offering a one-day workflow for simultaneous preparation of DNA and RNA libraries, using NGS technologies. In October, the company launched technologies for faster, simpler library preparation for NGS in RNA research.
Further, QIAGEN launched its upgraded GeneGlobe Design & Analysis Hub in September to provide next-level experiment planning, execution and follow-up to life science researchers.
The company launched QIAseq Expanded Carrier Screening Panel (a Sample to Insight solution) for research into genetic causes of rare and inherited diseases in June. In May, QIAGEN launched QIAstat-Dx syndromic testing system in the United States, after receiving FDA clearance. It also launched multiplex QIAstat-Dx Respiratory Panel in the same period.
Industry Prospects
Per a report by Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.